~~<i id='192D6AE892'><strike id='192D6AE892'><tt id='192D6AE892'><pre id='192D6AE892'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：focus 2025-08-12 00:10:07 Page View：21998

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 5 dead in mass shooting on Caribbean island of St. Vincent: Police
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Study finds new variant for Parkinson’s in African populations

AdobeAgroupofNigerian,British,andU.S.doctorshavediscoveredageneticvariantthatincreasestheriskofParki

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Complete sequence of Y chromosome published for first time

Akaryotype,orchromosomalprofileCDCTwoyearsago,whenaninternationalteamofscientistsannouncedithadfinal